Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Accounts Payables (2016 - 2025)

Historic Accounts Payables for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $2.3 million.

  • China Pharma Holdings' Accounts Payables rose 3719.89% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 3719.89%. This contributed to the annual value of $2.2 million for FY2024, which is 436.81% down from last year.
  • According to the latest figures from Q3 2025, China Pharma Holdings' Accounts Payables is $2.3 million, which was up 3719.89% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Accounts Payables registered a high of $3.1 million during Q2 2021, and its lowest value of $1.6 million during Q2 2024.
  • For the 5-year period, China Pharma Holdings' Accounts Payables averaged around $2.1 million, with its median value being $2.2 million (2025).
  • Examining YoY changes over the last 5 years, China Pharma Holdings' Accounts Payables showed a top increase of 66818.75% in 2021 and a maximum decrease of 5025.21% in 2021.
  • China Pharma Holdings' Accounts Payables (Quarter) stood at $1.9 million in 2021, then grew by 26.85% to $2.4 million in 2022, then decreased by 4.49% to $2.3 million in 2023, then decreased by 4.37% to $2.2 million in 2024, then rose by 5.51% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, $2.3 million for Q2 2025, and $2.2 million during Q1 2025.